The number of shares of common stock outstanding on March 15, 2021 was 28,567,298. & Meilleur also has an& option& to commercialize worldwide. & Navidea owns 100% of the outstanding shares of Navidea Europe. & Tc99m tilmanocept has not yet received marketing approval in India. & See Item 1A - "Risk Factors." & We also face competition from universities and other non-profit research organizations. These patents and/or applications are expected to expire between 2034 and 2040. & We believe that we are in substantial compliance with such governmental regulations. The existence of a SPA, however, does not assure approval of a product candidate. & In certain countries, the sales price of a product must also be approved. The MT Board has taken no action in response. & The Company has opposed Dr. Goldberg's requests. & The Delaware Court requested post-trial briefing and a post-trial hearing.& MT opposed Dr. Goldberg's filings.& Shares of our Common Stock are common equity interests. As a result, most research programs will not generate financial returns. The biotech and pharmaceutical industries are intensely competitive. To remain competitive, we must continue to launch new products and technologies. We may not be able to maintain compliance with our internal controls and procedures. & The Company does not intend to renew this lease. There were no repurchases of our Common Stock during the year ended December& 31, 2020. & Selling, General and Administrative Expenses. During 2020 and 2019, we recorded interest expense of $7,000 and $8,000, respectively. & See Notes 2 and 14 to the accompanying consolidated financial statements. & We also earn revenues related to our licensing and distribution agreements. R&D expenses are charged to operations as incurred. This results in a deemed dividend at the date of issuance for the amount of the BCF. S. Kathryn Rouan, Ph.D., has served as a director of Navidea since December 2018. Dr. Rosol holds a Ph.D. from Boston University School of Medicine. & The code of business conduct and ethics is posted on our website at www.navidea.com. Philosophy and Goals of Executive Compensation Plans. c) Dr. Rosol received an increase in his base salary effective February 1, 2020. The options will expire on the tenth anniversary of the date of grant. & The Second Circuit held oral argument in this matter on September 5, 2019. On September 2, 2020, the New York Supreme Court granted the Motion to Dismiss. However, Platinum-Montaur has not yet perfected that appeal. Mr. Rice and Dr. Bruck remain members of the board of directors of Navidea. Dr. Goldberg retains the ability to re-file the action in Delaware. Dr. Goldberg has not yet re-filed his derivative complaint. Navidea owns the remainder of the MT Common Stock. Principal Accountant Fees and Services & Audit Fees. 23.1 & Consent of Marcum LLP.* & & & Actual results could differ from those estimates. & & Total shares authorized under the 2014 Plan is 1,750,000 shares. Net realizable value is determined based on estimated sales activity and margins. Intangible assets are stated at cost, less accumulated amortization. Patent application costs are deferred pending the outcome of patent applications. 2018-10, Codification Improvements to Topic 842, Leases, and ASU No. In August 2018, the FASB issued ASU No. In exchange for such rights, the Company was entitled to certain royalty payments. & On May 18, 2020, the Lender funded the PPP Loan in the amount of $366,000. The P
